My Blue Dots

DUBLIN–(BUSINESS WIRE)–ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer’s, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial me

VANCOUVER, British Columbia–(BUSINESS WIRE)– #biotech–Aspect Biosystems secures $115M Series B to advance bioprinted tissue therapeutics, accelerating development of functional cures for serious diseases

DENVER–(BUSINESS WIRE)–Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, is scheduled to report fourth quarter and full year 2024 financial results after the close of trading on the New York Stock Exchange on Monday, February 3, 2025. Healthpeak will host a conference call and webcast on Tuesday, February 4, 2025, at 8:00 a.m. Mountain Time (10:00 a.m. Eastern Time) to review its financial performance and op

PLYMOUTH, Mass.–(BUSINESS WIRE)–GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST. Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment. The acquisition includes lead molecule, IDR